144 related articles for article (PubMed ID: 17992685)
1. Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice.
Hirst SJ; Ferger B
Synapse; 2008 Feb; 62(2):85-90. PubMed ID: 17992685
[TBL] [Abstract][Full Text] [Related]
2. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
3. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
[TBL] [Abstract][Full Text] [Related]
4. Acoustic startle response, prepulse inhibition, and spontaneous locomotor activity in MPTP-treated mice.
Leng A; Yee BK; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):449-56. PubMed ID: 15313033
[TBL] [Abstract][Full Text] [Related]
5. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization.
Shen YQ; Hebert G; Lin LY; Luo YL; Moze E; Li KS; Neveu PJ
J Neuroimmunol; 2005 Jan; 158(1-2):14-25. PubMed ID: 15589033
[TBL] [Abstract][Full Text] [Related]
6. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
7. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
[TBL] [Abstract][Full Text] [Related]
8. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
9. Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice.
Byler SL; Boehm GW; Karp JD; Kohman RA; Tarr AJ; Schallert T; Barth TM
Behav Brain Res; 2009 Mar; 198(2):434-9. PubMed ID: 19070633
[TBL] [Abstract][Full Text] [Related]
10. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
[TBL] [Abstract][Full Text] [Related]
11. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.
Koga K; Mori A; Ohashi S; Kurihara N; Kitagawa H; Ishikawa M; Mitsumoto Y; Nakai M
Eur J Neurosci; 2006 Feb; 23(4):1077-81. PubMed ID: 16519673
[TBL] [Abstract][Full Text] [Related]
12. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.
Luchtman DW; Shao D; Song C
Physiol Behav; 2009 Aug; 98(1-2):130-8. PubMed ID: 19410592
[TBL] [Abstract][Full Text] [Related]
13. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T
Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265
[TBL] [Abstract][Full Text] [Related]
14. Ethylenebisdithiocarbamate enhances MPTP-induced striatal dopamine depletion in mice.
McGrew DM; Irwin I; Langston JW
Neurotoxicology; 2000 Jun; 21(3):309-12. PubMed ID: 10894120
[TBL] [Abstract][Full Text] [Related]
15. Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent.
Filipov NM; Norwood AB; Sistrunk SC
Neuroreport; 2009 May; 20(7):713-7. PubMed ID: 19349914
[TBL] [Abstract][Full Text] [Related]
16. Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
Knaryan VH; Samantaray S; Varghese M; Srinivasan A; Galoyan AA; Mohanakumar KP
Neuropeptides; 2006 Aug; 40(4):291-8. PubMed ID: 16712929
[TBL] [Abstract][Full Text] [Related]
17. Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.
Quinn LP; Stean TO; Chapman H; Brown M; Vidgeon-Hart M; Upton N; Billinton A; Virley DJ
J Neurosci Methods; 2006 Sep; 156(1-2):218-27. PubMed ID: 16626808
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
Landau AM; Kouassi E; Siegrist-Johnstone R; Desbarats J
Mov Disord; 2007 Feb; 22(3):403-7. PubMed ID: 17230468
[TBL] [Abstract][Full Text] [Related]
20. The effect of dopamine on MPTP-induced rotarod disability.
Ayton S; George JL; Adlard PA; Bush AI; Cherny RA; Finkelstein DI
Neurosci Lett; 2013 May; 543():105-9. PubMed ID: 23562518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]